ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
(EAA) GUIDELINES ON KLINEFELTER SYNDROME
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 187670" data-attributes="member: 13851"><p><strong>European Academy of Andrology <span style="color: rgb(184, 49, 47)">(EAA) </span>GUIDELINES ON KLINEFELTER SYNDROME Endorsing Organisation: <span style="color: rgb(44, 130, 201)">European Society of Endocrinology </span></strong></p><p></p><p></p><p><span style="color: rgb(184, 49, 47)">Abstract </span></p><p></p><p><strong>Background: </strong>Knowledge about Klinefelter Syndrome (KS) has increased substantially since its first description almost 80 years ago. A variety of treatment options concerning the spectrum of symptoms associated with KS exists, also regarding aspects beyond testicular dysfunction. Nevertheless, the diagnostic rate is still low in relation to the prevalence and no international guidelines are available for KS.</p><p></p><p><strong>Objective:</strong> <em><span style="color: rgb(184, 49, 47)">To create the first European Academy of Andrology (EAA) guidelines on KS.</span></em></p><p></p><p><strong>Methods:</strong> An expert group of academicians appointed by the EAA generated a consensus guideline according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) system.</p><p></p><p><strong>Results:</strong> Clinical features are highly variable among patients with KS, although common characteristics are severely attenuated spermatogenesis and Leydig cell impairment, resulting in azoospermia and hypogonadotropic hypogonadism. In addition, various manifestations of neurocognitive and psycho-social phenotypes have been described as well as an increased prevalence of adverse cardiovascular, metabolic, and bone-related conditions which might explain the increased morbidity/mortality in KS. Moreover, compared to the general male population, a higher prevalence of dental, coagulation, and autoimmune disorders is likely to exist in patients with KS. Both genetic and epigenetic effects due to the supernumerary X- chromosome as well as testosterone deficiency contribute to this pathological pattern. The majority of patients with KS are diagnosed during adulthood, but symptoms can already become obvious during infancy, childhood, or adolescence. The pediatric and juvenile patients with KS require specific attention regarding their development and fertility.</p><p></p><p><strong>Conclusion:</strong> <span style="color: rgb(184, 49, 47)"><em>These guidelines provide recommendations and suggestions to care for patients with KS in various developmental stages ranging from childhood and adolescence to adulthood. This advice is based on recent research data and respective evaluations as well as validations performed by a group of experts.</em></span></p><p></p><p></p><p></p><p></p><p></p><p><span style="color: rgb(0, 0, 0)"><strong>GENETIC ISSUES</strong></span></p><p><strong>CHILDREN AND PRE-PUBERTAL BOYS WITH KS </strong></p><p><strong>ADOLESCENTS WITH KS</strong></p><p><strong>ADULTS WITH KS </strong></p><p><strong>GENERAL DEMANDS </strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>1. INTRODUCTION </strong></p><p></p><p><span style="color: rgb(184, 49, 47)">Klinefelter Syndrome (KS) is the most frequent chromosome disorder in men, exhibiting a karyotype of 47, XXY. Symptoms in KS are highly variable.</span> <span style="color: rgb(44, 130, 201)"><em>Nevertheless, frequent characteristics are small testes, azoospermia, and hypergonadotropic hypogonadism. Also neurocognitive and psycho-social manifestations can be seen as well as cardiovascular, metabolic, and bone-related conditions of adverse nature. </em></span>Generally, morbidity and mortality are increased in KS compared to men with a karyotype of 46, XY. Both hypogonadism and genetic effects seem to contribute to this clinical spectrum. Among physicians, knowledge about KS regarding diagnosis and treatment is distributed unevenly. KS is not fully known to many physicians and there is a marked need for a respective improvement of medical curricula.</p><p></p><p>Whereas KS is usually considered in all guidelines dealing with the management of hypogonadism, no specific guideline and recommendation have ever been published to care for patients with KS in various developmental stages. <span style="color: rgb(184, 49, 47)"><em>The aim of the present study is to summarize the available evidence on KS providing a list of suggestions and recommendations on behalf of the European Academy of Andrology (EAA) and endorsed by the European Society of Endocrinology in order to correctly manage patients with KS from prenatal period to adulthood.</em></span></p><p></p><p></p><p></p><p></p><p></p><p><span style="color: rgb(0, 0, 0)"><strong>2. METHODOLOGY OF THE GUIDELINE COMPOSITION </strong></span></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>2.1. Data identification </strong></span></p><p><span style="color: rgb(184, 49, 47)"><strong>2.2. Levels of evidence and grades of recommendation</strong></span></p><p><span style="color: rgb(184, 49, 47)"><strong>2.3. Aetiology</strong></span></p><p><span style="color: rgb(184, 49, 47)"><strong>2.4. Prevalence </strong></span></p><p><span style="color: rgb(184, 49, 47)"><strong>2.5. Low diagnostic rate</strong></span></p><p></p><p></p><p></p><p><span style="color: rgb(0, 0, 0)"><strong>3. CLINICAL PICTURES, DIAGNOSTIC STEPS, AND THERAPY </strong></span></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>3.1. Genetics</strong></span></p><p></p><p><strong><span style="color: rgb(0, 0, 0)">3.2. Developmental issues in infants and prepubertal children </span></strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)">3.2.1. Testicular development and function of the hypothalamic-pituitary-testicular axis </span></strong></p><p><strong><span style="color: rgb(184, 49, 47)">3.2.2. Growth </span></strong></p><p><strong><span style="color: rgb(184, 49, 47)">3.2.3. Bone mineralization </span></strong></p><p><strong><span style="color: rgb(184, 49, 47)">3.2.4. Body composition</span></strong></p><p><strong><span style="color: rgb(184, 49, 47)">3.2.5. Psychological aspects</span></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong><span style="color: rgb(0, 0, 0)">4.4. Developmental issues in puberty and adolescence </span></strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)">4.4.1. Spermatogenesis</span></strong></p><p><strong><span style="color: rgb(184, 49, 47)">4.3.2. Function of the hypothalamic-pituitary-testicular axis</span></strong></p><p><span style="color: rgb(184, 49, 47)"><strong>4.3.3. Cognitive and psychological aspects </strong></span></p><p></p><p></p><p></p><p><span style="color: rgb(0, 0, 0)"><strong>3.3. Pathophysiology and clinics in adults </strong></span></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>3.4. 4.4.1. Hypogonadism</strong></span></p><p><span style="color: rgb(184, 49, 47)"><strong>4.4.2. Infertility </strong></span></p><p><strong><span style="color: rgb(184, 49, 47)">4.4.3. Metabolic disorders, body composition, cardiovascular risk and thrombosis </span></strong></p><p><strong><span style="color: rgb(184, 49, 47)">4.4.4. Bone disorders </span></strong></p><p><strong><span style="color: rgb(184, 49, 47)">4.4.5. Psychological and psychiatric conditions/ Gender incongruence</span></strong></p><p><strong><span style="color: rgb(184, 49, 47)">4.4.6. Risk of neoplasia </span></strong></p><p><strong><span style="color: rgb(184, 49, 47)">4.4.7. Other disorders </span></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong><span style="color: rgb(0, 0, 0)">5. GENERAL DEMANDS</span></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>6. CONCLUSIONS AND FUTURE DIRECTIONS </strong></p><p></p><p><em><strong><span style="color: rgb(184, 49, 47)">KS is the most common sex chromosomal disorder in men. It affects patients with both hypogonadism and infertility. In addition, men with KS are afflicted with a higher risk of having cardiovascular, metabolic, psychiatric, and other comorbidities.</span></strong></em> <span style="color: rgb(44, 130, 201)"><strong><em>Providing the patient with KS and, if deemed adequate, his parents with suitable and balanced information as well as assistance for various aspects of his life after receiving the diagnosis is suggested. Prevention and treatment of the medical complications and comorbidities associated with KS should be standardized as far as possible. Also minimizing neurodevelopmental dysfunction, i.e. verbal deficits, learning difficulties, behavioral problems should be aimed at.</em></strong></span> <em><span style="color: rgb(184, 49, 47)"><strong>These measures are likely to promote the patients’ self-esteem, assure the quality of life, and improve his social adaption. Finally, preservation of the fertility potential, i.e. cryopreservation of spermatozoa from ejaculate or testicular tissue is an option now widely available. </strong></span></em></p><p></p><p><strong><em><span style="color: rgb(44, 130, 201)">The pathological conditions in patients with KS are most likely of a combined endocrine, genetic, and epigenetic origin.</span></em></strong> <em><strong><span style="color: rgb(184, 49, 47)">Further research in a coordinated fashion is needed. KS is vastly underdiagnosed and an increment of general knowledge, as well as establishment of standard care in multidisciplinary networks, is mandatory. These are the first guidelines to take a step towards this goal. </span></strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 187670, member: 13851"] [B]European Academy of Andrology [COLOR=rgb(184, 49, 47)](EAA) [/COLOR]GUIDELINES ON KLINEFELTER SYNDROME Endorsing Organisation: [COLOR=rgb(44, 130, 201)]European Society of Endocrinology [/COLOR][/B] [COLOR=rgb(184, 49, 47)]Abstract [/COLOR] [B]Background: [/B]Knowledge about Klinefelter Syndrome (KS) has increased substantially since its first description almost 80 years ago. A variety of treatment options concerning the spectrum of symptoms associated with KS exists, also regarding aspects beyond testicular dysfunction. Nevertheless, the diagnostic rate is still low in relation to the prevalence and no international guidelines are available for KS. [B]Objective:[/B] [I][COLOR=rgb(184, 49, 47)]To create the first European Academy of Andrology (EAA) guidelines on KS.[/COLOR][/I] [B]Methods:[/B] An expert group of academicians appointed by the EAA generated a consensus guideline according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) system. [B]Results:[/B] Clinical features are highly variable among patients with KS, although common characteristics are severely attenuated spermatogenesis and Leydig cell impairment, resulting in azoospermia and hypogonadotropic hypogonadism. In addition, various manifestations of neurocognitive and psycho-social phenotypes have been described as well as an increased prevalence of adverse cardiovascular, metabolic, and bone-related conditions which might explain the increased morbidity/mortality in KS. Moreover, compared to the general male population, a higher prevalence of dental, coagulation, and autoimmune disorders is likely to exist in patients with KS. Both genetic and epigenetic effects due to the supernumerary X- chromosome as well as testosterone deficiency contribute to this pathological pattern. The majority of patients with KS are diagnosed during adulthood, but symptoms can already become obvious during infancy, childhood, or adolescence. The pediatric and juvenile patients with KS require specific attention regarding their development and fertility. [B]Conclusion:[/B] [COLOR=rgb(184, 49, 47)][I]These guidelines provide recommendations and suggestions to care for patients with KS in various developmental stages ranging from childhood and adolescence to adulthood. This advice is based on recent research data and respective evaluations as well as validations performed by a group of experts.[/I][/COLOR] [COLOR=rgb(0, 0, 0)][B]GENETIC ISSUES[/B][/COLOR] [B]CHILDREN AND PRE-PUBERTAL BOYS WITH KS ADOLESCENTS WITH KS ADULTS WITH KS GENERAL DEMANDS 1. INTRODUCTION [/B] [COLOR=rgb(184, 49, 47)]Klinefelter Syndrome (KS) is the most frequent chromosome disorder in men, exhibiting a karyotype of 47, XXY. Symptoms in KS are highly variable.[/COLOR] [COLOR=rgb(44, 130, 201)][I]Nevertheless, frequent characteristics are small testes, azoospermia, and hypergonadotropic hypogonadism. Also neurocognitive and psycho-social manifestations can be seen as well as cardiovascular, metabolic, and bone-related conditions of adverse nature. [/I][/COLOR]Generally, morbidity and mortality are increased in KS compared to men with a karyotype of 46, XY. Both hypogonadism and genetic effects seem to contribute to this clinical spectrum. Among physicians, knowledge about KS regarding diagnosis and treatment is distributed unevenly. KS is not fully known to many physicians and there is a marked need for a respective improvement of medical curricula. Whereas KS is usually considered in all guidelines dealing with the management of hypogonadism, no specific guideline and recommendation have ever been published to care for patients with KS in various developmental stages. [COLOR=rgb(184, 49, 47)][I]The aim of the present study is to summarize the available evidence on KS providing a list of suggestions and recommendations on behalf of the European Academy of Andrology (EAA) and endorsed by the European Society of Endocrinology in order to correctly manage patients with KS from prenatal period to adulthood.[/I][/COLOR] [COLOR=rgb(0, 0, 0)][B]2. METHODOLOGY OF THE GUIDELINE COMPOSITION [/B][/COLOR] [COLOR=rgb(184, 49, 47)][B]2.1. Data identification 2.2. Levels of evidence and grades of recommendation 2.3. Aetiology 2.4. Prevalence 2.5. Low diagnostic rate[/B][/COLOR] [COLOR=rgb(0, 0, 0)][B]3. CLINICAL PICTURES, DIAGNOSTIC STEPS, AND THERAPY [/B][/COLOR] [COLOR=rgb(184, 49, 47)][B]3.1. Genetics[/B][/COLOR] [B][COLOR=rgb(0, 0, 0)]3.2. Developmental issues in infants and prepubertal children [/COLOR] [COLOR=rgb(184, 49, 47)]3.2.1. Testicular development and function of the hypothalamic-pituitary-testicular axis 3.2.2. Growth 3.2.3. Bone mineralization 3.2.4. Body composition 3.2.5. Psychological aspects[/COLOR] [COLOR=rgb(0, 0, 0)]4.4. Developmental issues in puberty and adolescence [/COLOR] [COLOR=rgb(184, 49, 47)]4.4.1. Spermatogenesis 4.3.2. Function of the hypothalamic-pituitary-testicular axis[/COLOR][/B] [COLOR=rgb(184, 49, 47)][B]4.3.3. Cognitive and psychological aspects [/B][/COLOR] [COLOR=rgb(0, 0, 0)][B]3.3. Pathophysiology and clinics in adults [/B][/COLOR] [COLOR=rgb(184, 49, 47)][B]3.4. 4.4.1. Hypogonadism 4.4.2. Infertility [/B][/COLOR] [B][COLOR=rgb(184, 49, 47)]4.4.3. Metabolic disorders, body composition, cardiovascular risk and thrombosis 4.4.4. Bone disorders 4.4.5. Psychological and psychiatric conditions/ Gender incongruence 4.4.6. Risk of neoplasia 4.4.7. Other disorders [/COLOR] [COLOR=rgb(0, 0, 0)]5. GENERAL DEMANDS[/COLOR] 6. CONCLUSIONS AND FUTURE DIRECTIONS [/B] [I][B][COLOR=rgb(184, 49, 47)]KS is the most common sex chromosomal disorder in men. It affects patients with both hypogonadism and infertility. In addition, men with KS are afflicted with a higher risk of having cardiovascular, metabolic, psychiatric, and other comorbidities.[/COLOR][/B][/I] [COLOR=rgb(44, 130, 201)][B][I]Providing the patient with KS and, if deemed adequate, his parents with suitable and balanced information as well as assistance for various aspects of his life after receiving the diagnosis is suggested. Prevention and treatment of the medical complications and comorbidities associated with KS should be standardized as far as possible. Also minimizing neurodevelopmental dysfunction, i.e. verbal deficits, learning difficulties, behavioral problems should be aimed at.[/I][/B][/COLOR] [I][COLOR=rgb(184, 49, 47)][B]These measures are likely to promote the patients’ self-esteem, assure the quality of life, and improve his social adaption. Finally, preservation of the fertility potential, i.e. cryopreservation of spermatozoa from ejaculate or testicular tissue is an option now widely available. [/B][/COLOR][/I] [B][I][COLOR=rgb(44, 130, 201)]The pathological conditions in patients with KS are most likely of a combined endocrine, genetic, and epigenetic origin.[/COLOR][/I][/B] [I][B][COLOR=rgb(184, 49, 47)]Further research in a coordinated fashion is needed. KS is vastly underdiagnosed and an increment of general knowledge, as well as establishment of standard care in multidisciplinary networks, is mandatory. These are the first guidelines to take a step towards this goal. [/COLOR][/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
(EAA) GUIDELINES ON KLINEFELTER SYNDROME
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top